Importantly, mAb-targeting TIGIT, with the property of co-engaging the crystallizable fragment (Fc) with the FcγR fragment, enable an improvement in response via a reduction in tumor volume, probably because of a reduction in Treg infiltrate and an increase in infiltration of NK immune cells and macrophages within the TME, leading to increased cytokine release [79,102]. The gene discussed is TIGIT; the disease is neoplasm.